UBS O'Connor’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

UBS O'Connor’s Portfolio LBPH Stock Details LBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-39,260	Closed	-$1.31M	–	624
2024 Q3	$1.31M	Sell	39,260 -12,336	-24%	-$425K	0.03%	246
2024 Q2	$1.39M	Sell	51,596 -2,457	-5%	-$48.5K	0.04%	248
2024 Q1	$1.17M	Sell	54,053 -69,153	-56%	-$1.51M	0.03%	260
2023 Q4	$743K	Sell	123,206 -139,059	-53%	-$693K	0.02%	305
2023 Q3	$1.46M	Hold	262,265	–	–	0.03%	288
2023 Q2	$1.93M	Buy	262,265 +32,265	+14%	+$244K	0.04%	300
2023 Q1	$904K	Buy	+230,000	New	+$1.12M	0.02%	424

UBS O'Connor's LBPH Position: Q4 2024 in Review

UBS O'Connor sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 39,260 shares — an estimated $1.31M sold.

UBS O'Connor first reported a position in LBPH in Q1 2023 and held it in 7 quarters. The position peaked at $1.93M in Q2 2023. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.

UBS O'Connor reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
UBS O'Connor sold 39,260 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $1.31M.
UBS O'Connor first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 7 quarters.
UBS O'Connor's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $1.93M in Q2 2023.
0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on UBS O'Connor's 13F filing for Q4 2024, filed 14 Feb 2025.